Nanotheranostic system for cancer with human safety energy device

2020 Fiscal Year Final Research Report

• Project/Area Number: 18H03523
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Basic Section 90110:Biomedical engineering-related
• Research Institution: Jikei University School of Medicine
• Principal Investigator: Mitsunaga Makoto 東京慈恵会医科大学, 医学部, 講師 (40433990)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: がん / 抗体療法 / 分子イメージング / 近赤外光 / 分子標的薬

Outline of Final Research Achievements

Molecular targeted therapies, such as monoclonal antibodies, were widely used for various cancers recently, leading to improve patients’ outcomes. Photoimmunotherapy (PIT) is a new class of molecular targeted cancer theranostics, which employs monoclonal antibody conjugated to a photosensitizer, IR700, that is activated by focal near-infrared (NIR) light irradiation leading to necrotic cell death. In this study, we developed a new type of PIT agents targeting VEGFR-2 expressed on vascular endothelium in a tumor stroma and Trop2 expressed on various types of cancer cell. We also developed photoactivatable functionalized liposome that can be used for PIT. Further study is needed for clinical translation,

Free Research Field

生体医工学

Academic Significance and Societal Importance of the Research Achievements

光免疫療法は再発頭頸部がん患者を対象として本邦においては臨床実用化に至った。本研究のように、光免疫療法の基盤技術を展開し新たな臨床応用へ繋げる検討は、がん患者の生命予後改善に寄与することが期待される。また、本研究による成果の創出は新たな研究開発のシーズにもなり得るため、社会的意義および学術的価値の高いものである。